Veterinary Therapeutics Market: Growth Trends, Drivers, and Outlook Through 2034
The global Veterinary Therapeutics Market is on a strong growth trajectory as pet ownership rises worldwide, livestock production intensifies, and the threat of zoonotic diseases pushes governments and animal health companies to invest in better treatment options. Covering veterinary drugs, vaccines, and medicated feed additives, this sector plays a critical role in safeguarding both animal well-being and public health by preventing the spread of diseases that can jump from animals to humans.
Market Size and Growth Projections
According to Fortune Business Insight, the global veterinary therapeutics market was valued at USD 47.25 billion in 2025. The market is projected to grow from USD 49.65 billion in 2026 to USD 81.59 billion by 2034, registering a compound annual growth rate (CAGR) of 6.40% during the forecast period. This steady expansion reflects the growing recognition among pet owners and livestock producers alike that proactive and reactive animal healthcare is no longer optional but essential.
Key Drivers Fueling Market Expansion
Several forces are converging to push this market forward. According to Fortune Business Insight, rising pet ownership, changing lifestyles, and stronger emotional bonds between humans and their animals are among the most significant drivers of demand for veterinary care and therapeutics. As more households welcome pets into their homes, owners are increasingly willing to spend on preventive care, wellness products, and treatments for chronic conditions.
The market is also witnessing a surge in new product launches, including innovative drugs, vaccines, and biologics designed to tackle a wide range of animal health issues. Regulatory approvals continue to support this momentum. According to Fortune Business Insight, in September 2024, Elanco received U.S. FDA approval for Zenrelia, a once-daily ilunocitinib tablet designed to control pruritus associated with allergic dermatitis in dogs aged 12 months and older.
The growing global demand for animal protein is another major factor. Livestock producers require effective disease prevention and treatment solutions to maintain healthy herds and flocks, especially as diseases such as foot and mouth disease, bovine mastitis, and tick-borne parasitic infections continue to threaten productivity. The presence of established animal health companies with strong R&D pipelines, including Zoetis Services LLC, Ceva, Virbac, and Merck Animal Health, further strengthens the competitive landscape and accelerates innovation.
Market Restraints and Challenges
Despite the positive outlook, the industry faces notable headwinds. Product recalls tied to safety and efficacy concerns remain a persistent challenge, often damaging brand reputation and eroding consumer trust. According to Fortune Business Insight, in June 2021 the UK's Veterinary Medicines Directorate issued a recall for a batch of Salmovac 400, a vaccine manufactured by CEVA Animal Health for Salmonella in chickens, due to safety concerns.
Antimicrobial resistance (AMR) also poses a growing challenge, particularly in lower-income countries where limited awareness and economic constraints contribute to the overuse of antibiotics in food-producing animals. According to Fortune Business Insight, the World Organization for Animal Health reported in September 2024 that antimicrobial resistance is projected to increase global healthcare costs by USD 189.0 billion by 2025, underscoring the scale of the issue and the need for stricter regulatory oversight.
Emerging Trends: Gene and Cell Therapies
One of the most exciting trends reshaping the industry is the emergence of gene and cell therapies for animals. These advanced treatments use genetic engineering to address hereditary conditions and offer personalized care tailored to an animal's specific health profile. According to Fortune Business Insight, in December 2024, Protect Animal Health partnered with Rejuvenate Bio to develop PT-401, a gene therapy targeting Myxomatous Mitral Valve Disease in dogs, aimed at delaying heart failure progression. Such collaborations signal a broader shift toward precision medicine in veterinary care, mirroring trends already well established in human healthcare.
Segmental Insights
Within the product landscape, veterinary drugs dominate the market. According to Fortune Business Insight, the veterinary drugs segment held the largest market share, at 64.87% in 2026, driven by the rising prevalence of animal diseases and continued regulatory approvals for generic and branded therapies.
By animal type, livestock therapeutics command a significant portion of the market. According to Fortune Business Insight, the livestock segment is anticipated to contribute 53.63% to the overall market share in 2026, while the companion animal segment is estimated to capture 46.1% of the market share in 2025, reflecting the dual importance of food security and pet health in shaping demand.
In terms of route of administration, parenteral delivery leads the way due to its rapid onset and precise dosing capabilities, particularly for vaccines and pain management. Meanwhile, veterinary clinics remain the preferred distribution channel, supported by the growing number of new clinic openings catering to small animal care.
Regional Outlook
North America continues to lead the global market. According to Fortune Business Insight, North America generated USD 18.91 billion in 2025, contributing 40.02% to global market revenue, and is projected to grow to USD 20.1 billion in 2026, supported by strong pet ownership rates and advanced veterinary infrastructure. The U.S. alone is expected to reach a valuation of USD 18.93 billion in 2026.
Europe follows as the second-largest regional market. According to Fortune Business Insight, Europe was valued at USD 12.01 billion in 2025 and is expected to reach USD 12.5 billion in 2026, driven by a large pet population and supportive government initiatives. Asia Pacific is also emerging as a key growth region, with the market reaching USD 8.37 billion in 2025 and projected to grow to USD 8.8 billion in 2026, fueled by expanding livestock production across countries like China, India, and Japan.
Competitive Landscape
The market remains fairly consolidated around a handful of major players. According to Fortune Business Insight, Zoetis Services LLC, Merck Animal Health, and Elanco are among the most prominent companies shaping the global market, supported by robust product portfolios and consistent regulatory approvals. Other notable players, including Ceva, Vetoquinol, and Virbac, continue to expand their market presence through innovative product launches, strategic partnerships, and geographic expansion into emerging markets.
Conclusion
The veterinary therapeutics market is well-positioned for sustained growth through 2034, propelled by rising pet ownership, increasing demand for animal protein, and continuous innovation in drugs, vaccines, and feed additives. While challenges like product recalls and antimicrobial resistance remain areas of concern, the emergence of advanced therapies such as gene and cell treatments points toward a future where veterinary care becomes increasingly sophisticated and personalized. As key industry players continue to invest in research, regulatory approvals, and strategic collaborations, the market is set to play an even greater role in safeguarding animal and public health worldwide.
Source:https://www.fortunebusinessinsights.com/industry-reports/veterinary-therapeutics-market-100138